1. World Health Organization (WHO). IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Some N-Nitroso Compounds. Vol 17. France; 1978.
2. World Health Organization (WHO). Overall Evaluations of Carcinogenicity: an Updating of IARC Monographs Volumes 1 to 42. Lyon (FR); Vol 7., 1987.
3. U.S. Department of Health and Human Services. 2017. 14th Report on carcinogens. Available at: https://ntp.niehs.nih.gov/whatwestudy/assessments/cancer/roc/index.html#toc1. Accessed December 1,2020
4. European Medicines Agency. 2018. EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity: some valsartan medicines being recalled across the EU. Press Release. Available at: https://www.ema.europa.eu/en/news/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity-some. Accessed December 1, 2020.
5. U.S. Food & Drug Administration. 2018. FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity. Press Release. Available at:https://www.fda.gov/news-events/press-announcements/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity. Accessed December 1, 2020.